AAV1.NT3 Gene Therapy Mitigates the Severity of Autoimmune Encephalomyelitis in the Mouse Model for Multiple Sclerosis

Overview

Journal Gene Ther

Date 2025 Feb 19

PMID 39972161

Authors

Lingying Tong

Burcak Ozes

Kyle Moss

Morgan Myers

Zayed Attia

Tatyana A Vetter

Bruce D Trapp

Zarife Sahenk

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is an immune-mediated chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) affecting more than 2.5 million patients worldwide. Chronic demyelination in the CNS has an important role in perpetuating axonal loss and increases difficulty in promoting remyelination. Therefore, regenerative, and neuroprotective strategies are essential to overcome this impediment to rescue axonal integrity and function. Neurotrophin 3 (NT-3) has immunomodulatory and anti-inflammatory properties, in addition to its well-recognized function in nervous system development, myelination, neuroprotection, and regeneration. For this study, scAAV1.tMCK.NT-3 was delivered to the gastrocnemius muscle of experimental autoimmune encephalomyelitis (EAE) mice, the chronic relapsing mouse model of MS, at 3 weeks post EAE induction. Measurable NT-3 levels were found in serum at 7-weeks post gene delivery. The treated cohort showed improved clinical scores and performed significantly better in rotarod, and grip strength tests compared to their untreated counterparts. Histopathologic studies showed improved remyelination and axon protection. These data correlated with reduced expression of the pro-inflammatory cytokines in brain and spinal cord, and increased percentage of regulatory T cells in the spleens and lymph nodes. Collectively, these findings demonstrate the translational potential of AAV-delivered NT-3 for chronic progressive MS.

References

Rodriguez Murua S, Farez M, Quintana F . The Immune Response in Multiple Sclerosis. Annu Rev Pathol. 2021; 17:121-139. DOI: 10.1146/annurev-pathol-052920-040318. View

Dendrou C, Fugger L, Friese M . Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015; 15(9):545-58. DOI: 10.1038/nri3871. View

Trapp B, Peterson J, Ransohoff R, Rudick R, Mork S, Bo L . Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338(5):278-85. DOI: 10.1056/NEJM199801293380502. View

Wujek J, Bjartmar C, Richer E, Ransohoff R, Yu M, Tuohy V . Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol. 2002; 61(1):23-32. DOI: 10.1093/jnen/61.1.23. View

Dutta R, Trapp B . Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007; 68(22 Suppl 3):S22-31. DOI: 10.1212/01.wnl.0000275229.13012.32. View

Bebo B, Cintina I, LaRocca N, Ritter L, Talente B, Hartung D . The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs. Neurology. 2022; 98(18):e1810-e1817. PMC: 9109149. DOI: 10.1212/WNL.0000000000200150. View

Segal B . Stage-specific immune dysregulation in multiple sclerosis. J Interferon Cytokine Res. 2014; 34(8):633-40. PMC: 4128245. DOI: 10.1089/jir.2014.0025. View

Hu D, Notarbartolo S, Croonenborghs T, Patel B, Cialic R, Yang T . Transcriptional signature of human pro-inflammatory T17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017; 8(1):1600. PMC: 5693957. DOI: 10.1038/s41467-017-01571-8. View

Mahad D, Trapp B, Lassmann H . Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015; 14(2):183-93. DOI: 10.1016/S1474-4422(14)70256-X. View

10.

Hauser S, Cree B . Treatment of Multiple Sclerosis: A Review. Am J Med. 2020; 133(12):1380-1390.e2. PMC: 7704606. DOI: 10.1016/j.amjmed.2020.05.049. View

11.

Segal B . Modulation of the Innate Immune System: A Future Approach to the Treatment of Neurological Disease. Clin Immunol. 2018; 189:1-3. DOI: 10.1016/j.clim.2018.03.003. View

12.

Barbacid M . The Trk family of neurotrophin receptors. J Neurobiol. 1994; 25(11):1386-403. DOI: 10.1002/neu.480251107. View

13.

Huang E, Wilkinson G, Farinas I, Backus C, Zang K, Wong S . Expression of Trk receptors in the developing mouse trigeminal ganglion: in vivo evidence for NT-3 activation of TrkA and TrkB in addition to TrkC. Development. 1999; 126(10):2191-203. PMC: 2710120. DOI: 10.1242/dev.126.10.2191. View

14.

Sahenk Z . Neurotrophins and peripheral neuropathies. Brain Pathol. 2006; 16(4):311-9. PMC: 8096058. DOI: 10.1111/j.1750-3639.2006.00038.x. View

15.

Richner M, Ulrichsen M, Elmegaard S, Dieu R, Pallesen L, Vaegter C . Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system. Mol Neurobiol. 2014; 50(3):945-70. DOI: 10.1007/s12035-014-8706-9. View

16.

Meier C, Parmantier E, Brennan A, Mirsky R, Jessen K . Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci. 1999; 19(10):3847-59. PMC: 6782711. View

17.

Sekimoto M, Tsuji T, Matsuzaki J, Chamoto K, Koda T, Nemoto K . Functional expression of the TrkC gene, encoding a high affinity receptor for NT-3, in antigen-specific T helper type 2 (Th2) cells. Immunol Lett. 2003; 88(3):221-6. DOI: 10.1016/s0165-2478(03)00080-4. View

18.

Sahenk Z, Galloway G, Clark K, Malik V, Rodino-Klapac L, Kaspar B . AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther. 2013; 22(3):511-521. PMC: 3944324. DOI: 10.1038/mt.2013.250. View

19.

Ozes B, Moss K, Myers M, Ridgley A, Chen L, Murrey D . AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in mice. Brain Commun. 2021; 3(4):fcab252. PMC: 8568849. DOI: 10.1093/braincomms/fcab252. View

20.

Ozes B, Tong L, Myers M, Moss K, Ridgley A, Sahenk Z . AAV1.NT-3 gene therapy prevents age-related sarcopenia. Aging (Albany NY). 2023; 15(5):1306-1329. PMC: 10042697. DOI: 10.18632/aging.204577. View